CURE.DE vs. XDG3.DE
CURE.DE (VanEck Genomics and Healthcare Innovators UCITS ETF A) and XDG3.DE (Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C) are both Health & Biotech Equities funds - CURE.DE tracks the MVIS Global Future Healthcare ESG while XDG3.DE tracks the MSCI ACWI IMI SDG 3 Good Health and Well-being Select. Both are passively managed. Over the past 3 years, CURE.DE returned -2.48%/yr vs 1.94%/yr for XDG3.DE. A 0.61 correlation means they provide meaningful diversification when combined. Both charge a 0.35% expense ratio.
Performance
CURE.DE vs. XDG3.DE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CURE.DE achieves a -5.10% return, which is significantly higher than XDG3.DE's -6.02% return.
CURE.DE
- 1D
- 4.01%
- 1M
- 6.73%
- YTD
- -5.10%
- 6M
- -8.62%
- 1Y
- 6.04%
- 3Y*
- -2.48%
- 5Y*
- —
- 10Y*
- —
XDG3.DE
- 1D
- 2.88%
- 1M
- 2.53%
- YTD
- -6.02%
- 6M
- -6.54%
- 1Y
- 2.67%
- 3Y*
- 1.94%
- 5Y*
- —
- 10Y*
- —
CURE.DE vs. XDG3.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
CURE.DE VanEck Genomics and Healthcare Innovators UCITS ETF A | -5.10% | 5.09% | 0.30% | -7.74% |
XDG3.DE Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C | -6.02% | 1.47% | 9.58% | 2.52% |
Correlation
The correlation between CURE.DE and XDG3.DE is 0.68, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.68 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.61 |
Correlation (All Time) Calculated using the full available price history since Feb 13, 2023 | 0.61 |
The correlation between CURE.DE and XDG3.DE has been stable across timeframes, ranging from 0.61 to 0.68 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CURE.DE vs. XDG3.DE — Risk / Return Rank
CURE.DE
XDG3.DE
CURE.DE vs. XDG3.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C (XDG3.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CURE.DE | XDG3.DE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.13 | ||
| Sortino ratioReturn per unit of downside risk | +0.21 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 1.04 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 0.30 | 0.17 | +0.13 |
| Martin ratioReturn relative to average drawdown | 0.68 | 0.44 | +0.24 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CURE.DE | XDG3.DE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.29 | 0.16 | +0.13 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.14 | 0.16 | -0.30 |
Drawdowns
CURE.DE vs. XDG3.DE - Drawdown Comparison
The maximum CURE.DE drawdown since its inception was -34.80%, which is greater than XDG3.DE's maximum drawdown of -20.49%. Use the drawdown chart below to compare losses from any high point for CURE.DE and XDG3.DE.
Loading charts...
Drawdown Indicators
| CURE.DE | XDG3.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -34.80% | -20.49% | -14.31% |
Max Drawdown (1Y)Largest decline over 1 year | -19.07% | -13.31% | -5.76% |
Max Drawdown (3Y)Largest decline over 3 years | -29.32% | -20.49% | -8.83% |
Current DrawdownCurrent decline from peak | -15.66% | -11.91% | -3.75% |
Average DrawdownAverage peak-to-trough decline | -15.12% | -5.57% | -9.55% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.53% | 5.29% | +3.24% |
Volatility
CURE.DE vs. XDG3.DE - Volatility Comparison
VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) has a higher volatility of 5.73% compared to Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C (XDG3.DE) at 4.95%. This indicates that CURE.DE's price experiences larger fluctuations and is considered to be riskier than XDG3.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CURE.DE | XDG3.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.73% | 4.95% | +0.78% |
Volatility (6M)Calculated over the trailing 6-month period | 15.20% | 10.56% | +4.64% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.97% | 14.57% | +5.40% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.74% | 13.31% | +7.43% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 20.74% | 13.31% | +7.43% |
CURE.DE vs. XDG3.DE - Expense Ratio Comparison
Both CURE.DE and XDG3.DE have an expense ratio of 0.35%.
Dividends
CURE.DE vs. XDG3.DE - Dividend Comparison
Neither CURE.DE nor XDG3.DE has paid dividends to shareholders.
Frequently Asked Questions
CURE.DE and XDG3.DE have a correlation of 0.68, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Both ETFs have the same 0.35% expense ratio. The better choice depends on whether you care most about return, fees, risk, or income.
CURE.DE and XDG3.DE have the same expense ratio: 0.35% per year.
CURE.DE tracks MVIS Global Future Healthcare ESG, while XDG3.DE tracks MSCI ACWI IMI SDG 3 Good Health and Well-being Select. They also come from different issuers: VanEck and Xtrackers.
Find the right allocation for CURE.DE and XDG3.DE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer